Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07572929
PHASE2

A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant

Sponsor: Medical College of Wisconsin

View on ClinicalTrials.gov

Summary

This is a prospective, open-label investigation to determine whether measurable residual disease (MRD) guided assignment of maintenance therapy is effective in patients with myeloid malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). Pre-HCT, patients will undergo usual disease assessments which should include immunophenotypic and/or molecular testing. Based on the results of these tests, patients may or may not be recommended to receive maintenance therapy post-transplant, depending on the presence or absence of a residual malignant clone.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

450

Start Date

2026-08-01

Completion Date

2034-02-01

Last Updated

2026-06-23

Healthy Volunteers

No

Interventions

DRUG

Maintenance Therapy

Maintenance therapy will be suggested by the PIs, however final choice of maintenance is at the discretion of the treating physician.

OTHER

No intervention

Patients will receive no maintenance therapy.

Locations (1)

Froedtert & the Medical College of Wisconsin

Milwaukee, Wisconsin, United States